Yükleniyor... / Loading...
This study examined the radiosensitizing and radioprotective effects of Curcumin compared with placebo during radiotherapy for prostate cancer. It included patients aged 50-80 with histologically confirmed prostate adenocarcinoma. The study was carried out as a non-phase study and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: 1. Histologically confirmed adenocarcinoma of the prostate 2. Age range of 50-80 3. ECOG performance status 0-1 4. Life expectancy \> 5 years 5. Must be enrolled in a social security program 6. No other cancer, except basal cell skin cancer, that has been treated or relapsed within the past 5 years 7. No severe uncontrolled hypertension (systolic BP ≥ 160 mm Hg or diastolic BP ≥ 90 mm Hg) 8. No contraindication to luteinizing hormone-releasing hormone agonists 9. No contraindication to pelvic irradiation (e.g., scleroderma, chronic inflammatory gastrointestinal disease) 10. No hip prosthesis 11. Must not be deprived of liberty or under guardianship 12. No geographical, social, or psychological reasons that would preclude follow up Exclusion Criteria: 1. Clinical stage T3 or T4 2. Gleason score ≥ 8 3. Serum PSA ≥ 20 ng/mL and ≤ 100 ng/mL 4. other prior surgery for prostate cancer 5. concurrent participation in another clinical trial which would require approval upon entry to this trial 6. Gastrointestinal disorders such as IBD, reflux and peptic ulcers 7. Any adverse reaction to curcumin